Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$10.03 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)517.12K
Market Cap
$191.45M
Enterprise Value$10.30M
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 10, 2026EPS Estimate
-2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.66
Shares Outstanding15,940,801
10 Day Avg. Volume630,117
30 Day Avg. Volume517,116
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$43.50Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.93
Revenue Forecast (FY)$30.05M
Bulls Say, Bears Say
Bulls Say
Expanded Payer CoverageMaterial expansion of TONMYA reimbursement meaningfully increases the addressable treated population and structural access to prescriptions. Durable payer coverage reduces barriers to uptake, supports sustained prescription volumes over months, and improves revenue visibility if clinical adoption follows.
Diversified Clinical Pipeline ProgressMultiple positive early-stage programs across immunology, infectious disease, and CNS increase the probability of value-creating milestones. This diversified R&D portfolio spreads scientific risk, creates multiple partnership/commercialization optionalities, and supports longer-term growth beyond a single product.
Low Financial LeverageVery low debt reduces solvency and interest-rate stress and preserves strategic flexibility to fund R&D or pursue partnerships. With minimal leverage, Tonix can prioritize equity or milestone-based deals over debt, lowering fixed financial obligations while advancing clinical programs.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow creates structural funding pressure and shortens runway absent material revenue or financing. Ongoing cash consumption increases the need for dilutive raises or deals, limiting financial optionality and placing calendar risk on clinical milestones and commercialization plans.
Reliance On External FinancingAs a clinical-stage company without consistent marketed revenues, Tonix remains fundamentally dependent on capital markets or partnerships to fund operations. This reliance creates execution risk: delays or weaker trial outcomes can force dilutive financings or scaled-back programs, constraining long-term value creation.
Share-Structure & Dilution RiskBoard authority to implement large reverse splits and a broad incentive plan signals potential listing-compliance and dilution risks. Such actions can presage future share consolidation or significant equity compensation, both of which can affect investor perception and materially alter shareholder dilution dynamics over the medium term.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $10.03 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $191.45M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on May 11, 2026. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$2.57 by -$0.36.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.55.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 15,940,801 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$2.93 in its last earnings report, missing expectations of -$2.57. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.50 (188.46% Upside)
$43.50 (188.46% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $418.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.00%
12-Months-Change
Fundamentals
Return on Equity
-67.65%
Trailing 12-Months
Asset Growth
33.72%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$43.50
▲(188.46% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
6.12% Mutual Funds
3.41% Other Institutional Investors
82.53% Public Companies and
Individual Investors